



February 2017

Drug Information Update

TABLE OF CONTENTS

NEWLY AVAILABLE GENERICS	2
NEW DRUG ENTITIES/COMBINATIONS/STRENGTHS	3
NEW INDICATIONS (EXISTING DRUGS)	4
FDA NEWS/BULLETINS/ADVISORIES/SAFETY ALERTS	6
STUDIES and RECENT TOPICS.....	7
RECALLS.....	11
CURRENT DRUG SHORTAGES.....	19

NEWLY AVAILABLE GENERICS

GENERIC DRUG NAME	STRENGTH & DOSAGE FORM	GENERIC MANUFACTURER	BRAND NAME
RIBAVIRIN	6 gram VIAL-NEB	ZYDUS PHARMACEU	VIRAZOLE
EPINEPHRINE	0.15mg/0.3mL AUTO INJCT	MYLAN	EPIPEN JR 2-PAK

NEW DRUG ENTITIES/COMBINATIONS/STRENGTHS

DESCRIPTION	BRAND NAME	GENERIC NAME	STRENGTH	NOTES
ANTIVIRALS, HIV-SPECIFIC, CCR5 CORECEPTOR ANTAG.	SELZENTRY	MARAVIROC	75 mg	New Strength
ANTIVIRALS, HIV-SPECIFIC, CCR5 CORECEPTOR ANTAG.	SELZENTRY	MARAVIROC	25 mg	New Strength
IBS – C/CIC AGENTS, GUANYLATE CYCLASE – C AGONIST	LINZESS	LINACLOTIDE	72 mcg	New Strength
TOPICAL LOCAL ANESTHETICS	ZEYOCAINE	LIDOCAINE/ KINESIOLOGY TAPE	5% KT OINT TP	New Dosage Form

NEW INDICATIONS (EXISTING DRUGS)

Symbicort®

January 25, 2017

AstraZeneca today announced that the US Food and Drug Administration (FDA) granted six months of pediatric exclusivity for Symbicort® (budesonide/formoterol) Inhalation Aerosol. The FDA's decision was based on the evaluation of trials conducted in children with asthma aged six up to 12 years in response to a Written Request (a prerequisite for qualifying for pediatric exclusivity under Section 505A of the Federal Food, Drug, and Cosmetic Act). Symbicort® is currently approved in the US to treat asthma in patients 12 years and older and for the maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD) in adults.

Source: AstraZeneca

<https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2017/symbicort-granted-paediatric-exclusivity-in-the-us-26012017.html>

NARCAN®

January 25, 2017

Today, the U.S. Food and Drug Administration (FDA) approved NARCAN® Nasal Spray as a 2mg formulation for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. The 2mg dose is approved for use in opioid-dependent patients expected to be at risk for severe opioid withdrawal in situations where there is a low risk for accidental or intentional opioid exposure by household contacts.

Source: Adapt Pharma

http://adaptpharma.com/adapt_press_release/january-25-2017-narcan-nasal-spray-2mg-approved-by-us-food-and-drug-administration/

LINZESS®

January 26, 2017

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Allergan plc (NYSE: AGN) announced today that the U.S. Food and Drug Administration (FDA) has approved a 72 mcg dose of LINZESS® (linaclotide) for the treatment of chronic idiopathic constipation (CIC) in adult patients.

Source: Ironwood Pharmaceuticals, Inc.

<http://news.ironwoodpharma.com/phoenix.zhtml?c=228069&p=irol-newsArticle&ID=2239965>

Latuda®

January 28, 2017

Sunovion Pharmaceuticals Inc. (Sunovion) today announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for Latuda® (lurasidone HCl) for the treatment of schizophrenia in adolescents aged 13 to 17 years. LATUDA is also approved in the U.S. for the treatment of adults with schizophrenia and for the treatment of adults with major depressive episodes associated with bipolar I disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate.

Source: Sunovion Pharmaceuticals Inc.

<http://www.sunovion.com/news/pressReleases/20170128.pdf>

XYZAL® ALLERGY 24HR

February 1, 2017

Sanofi announced today that the U.S. Food and Drug Administration (FDA) approved Xyzal® Allergy 24HR as an over-the-counter (OTC) treatment for the relief of symptoms associated with seasonal and year-round allergies. Specifically, two formulations of Xyzal are now approved for OTC use – 5 mg tablets for ages 6 years and older, as well as 0.5 mg/mL oral solution for ages 2 years and older. Xyzal is an oral antihistamine with a proven 24-hour effect.

Source: Sanofi

<http://www.news.sanofi.us/2017-02-01-Sanofis-Xyzal-R-Allergy-24HR-Approved-for-Over-the-Counter-Use-in-the-United-States>

Opdivo®

February 2, 2017

Bristol-Myers Squibb Company (NYSE:BMJ) today announced the U.S. Food and Drug Administration (FDA) has approved Opdivo® injection, for intravenous use for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC) who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. The recommended dose for mUC is 240 mg administered as an intravenous infusion over 60 minutes every two weeks until disease progression or unacceptable toxicity. In the CheckMate -275 trial, 19.6% (95% CI: 15.1- 24.9; 53/270) of patients responded to treatment with Opdivo. The percentage of patients with a complete response was 2.6% (7/270) and the percentage of patients with a partial response was 17% (46/270). Among responders, the median duration of response was 10.3 months (range: 1.9+-12.0+ months). The median time to response was 1.9 months (range: 1.6-7.2).

Source: Bristol-Myers Squibb Company

<http://news.bms.com/press-release/bladdercancer/bristol-myers-squibb-receives-fda-approval-opdivo-nivolumab-previously-t&t=636226683913405799>

FDA NEWS/BULLETINS/ADVISORIES/SAFETY ALERTS

Certain Homeopathic Teething Products: FDA Warning - Confirmed Elevated Levels of Belladonna [Posted 01/27/2017]

ISSUE: FDA announced that its laboratory analysis found inconsistent amounts of belladonna, a toxic substance, in certain homeopathic teething tablets, sometimes far exceeding the amount claimed on the label. The agency is warning consumers that homeopathic teething tablets containing belladonna pose an unnecessary risk to infants and children and urges consumers not to use these products. In light of these findings, the FDA contacted Standard Homeopathic Company in Los Angeles, the manufacturer of Hyland's homeopathic teething products, regarding a recall of its homeopathic teething tablet products labeled as containing belladonna, in order to protect consumers from inconsistent levels of belladonna. At this time, the company has not agreed to conduct a recall.

BACKGROUND: Homeopathic teething products have not been evaluated or approved by the FDA for safety or effectiveness. The agency is unaware of any proven health benefit of the products, which are labeled to relieve teething symptoms in children. In September 2016, the FDA warned against the use of these products after receiving adverse event reports. In November 2016, Raritan Pharmaceuticals (East Brunswick, New Jersey) recalled three belladonna-containing homeopathic products, two of which were marketed by CVS.

RECOMMENDATION: The FDA recommends that consumers stop using these products marketed by Hyland's immediately, and dispose of any in their possession. Consumers should seek medical care immediately if their child experiences seizures, difficulty breathing, lethargy, excessive sleepiness, muscle weakness, skin flushing, constipation, difficulty urinating, or agitation after using homeopathic teething products. Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:

- Complete and submit the report Online: www.fda.gov/MedWatch/report
- Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

Source: U.S. Food and Drug Administration (FDA)

STUDIES and RECENT TOPICS

Patients are increasingly asking docs about drugs in DTC ads: poll

January 26, 2017

A new study by market research firm in Crowd revealed that patients are increasingly asking their doctors about drugs featured in direct-to-consumer ads. According to the study, doctors reported that patients raised questions about a drug from an ad six times in a typical week, compared to just twice in a typical week five years ago.

Source: mmm-online.com

NicoDerm Introduces New Nicotine Eye Patch

January 27, 2016

Praising the product as an effective and convenient means of helping individuals quit smoking, pharmaceutical manufacturer GlaxoSmithKline announced Wednesday the release of its new NicoDerm eye patch. “These discreet and easy-to-use eye patches allow users to curb their cigarette cravings by delivering a steady flow of therapeutic nicotine directly into the bloodstream through the optic nerve,” said company spokesperson Caitlin Timmons, adding that the user simply removes the backing from the patch and applies the adhesive layer directly on their exposed cornea. “Individuals can choose to place the patch on their left eye or right eye, and the extended-release technology will reduce withdrawal symptoms for up to 72 hours. We recommend, however, that users don’t put on more than one at a time.” Officials told reporters that the NicoDerm eye patch might cause side effects such as trouble sleeping, burning at the application site, and poor depth perception.

Source: theonion.com

Houston Company’s immunotherapy treatment gets special FDA status

January 27, 2017

The drug, Viralym-C, was developed to treat cytomegalovirus, known as CMV, an infection that while not uncommon and typically benign, can cause serious health problems and even death for people with weakened immune systems. It can also be harmful to babies infected with the virus before they are born.

Source: chron.com

Drug Makers Accused of Fixing Prices on Insulin

January 30, 2017

A lawsuit filed Monday accused three makers of insulin of conspiring to drive up the prices of their lifesaving drugs, harming patients who were being asked to pay for a growing share of their drug bills.

The price of insulin has skyrocketed in recent years, with the three manufacturers — Sanofi, Novo Nordisk and Eli Lilly — raising the list prices of their products in near lock step, prompting outcry from patient groups and doctors who have pointed out that the rising prices appear to have little to do with increased production costs.

Source: nytimes.com

Older adults who take many medications have a higher risk for becoming frail

February 1, 2017

As we age, we tend to develop a number of chronic health conditions and concerns. Often, managing health problems can mean that older adults may take many different medications. When older adults take five or more medicines (a scenario called "polypharmacy" by health experts), it can increase the risk for harmful side effects.

Source: eurekaalert.org

Hormone Blockers Can Prolong Life if Prostate Cancer Recurs

February 1, 2017

Men whose prostate cancer comes back after surgery are more likely to survive if, along with the usual radiation, they also take drugs to block male hormones. The finding, published Wednesday in The New England Journal of Medicine, comes from a long-running study that experts say will help clarify treatment for many patients.

Source: nytimes.com

Want to build better patient relationships? Take a page from consumer marketers, advises Harvard fellow

February 1, 2017

Consumer companies know how to use data to build customer relationships, create trust and craft better experiences. Who better for healthcare companies to learn from? So Kathy Giusti, a senior fellow and co-chair of the Kraft Precision Medicine Accelerator at the Harvard Business School, organized a workshop at Harvard to make that happen. In this case, she specifically brought in direct-to-patient cancer organizations—including the group she cofounded, the Multiple Myeloma Research Foundation—to listen and learn. But the best in class ideas and strategies can be put to work across the healthcare and pharma landscape, she said.

Source: fiercepharma.com

Merck campaign shows impact of shingles

February 2, 2017

Most advertisements for prescription drugs are bright, cheerful, and uplifting. But Merck's advertisements for shingles vaccine Zostavax took a decidedly different route. The ads feature a woman, Linda, swimming alone in a pool while an ominous voice-over, the shingles virus personified, tells Linda that she is susceptible to the disease without her even knowing it. The threatening narration, accompanied by unsettling music and images of the shingles rash, tops off the ad's scare factor.

Source: mmm-online.com

Common pain relievers may increase heart attack risk during respiratory infections

February 2, 2017

Widely used pain relievers may increase the risk of a heart attack when used during a cold or flu-like illness, according to a new study published in the Journal of Infectious Diseases. The findings suggest physicians and patients should use caution when prescribing or taking the medications, known as nonsteroidal anti-inflammatory drugs, or NSAIDs, to ease symptoms of acute respiratory infections.

Source: medicalxpress.com

Senator asks Kaleo to explain \$4,500 pricetag for overdose, allergy devices

February 3, 2017

Senator Amy Klobuchar wants drugmaker Kaleo to explain the \$4,500 price tags on its autoinjector devices for opioid overdose and food allergies. "Due to the severity of the opioid epidemic and Evzio's life-saving attributes, it is critical that your products remain affordable to Americans," Klobuchar wrote in a letter to Kaleo CEO Spencer Williamson.

Source:cnbc.com

The top 15 would-be blockbusters in the pipeline prepping for a 2017 launch

February 3, 2017

This is the year that a whole slate of Big Pharmas should be able to score bragging rights to blockbuster drug launches. And after last year's paltry roundup of new drug approvals, they all desperately need it. Every year Evaluate Pharma likes to do its breakdown of the top 20 small molecules and biologics aiming to hit the market, ranked by estimated 2022 sales. (Being a bit agnostic about this, we mashed the two lists into one and ranked them all by peak sales forecasts.)

Source: endpts.com

Antibiotic Significantly Cuts Recurrent C. difficile Infection

February 5, 2017

Rach Researchers have seen a nearly 40% reduction in recurrent Clostridium difficile (C. difficile) infections when using the antibiotic bezlotoxumab. Researchers from the University of Leeds conducted two phase 3 trials called MODIFY I and MODIFY II to determine if actoxumab or bezlotoxumab were effective in preventing recurrent infection within 12 weeks after infusion. The researchers explained that both actoxumab and bezlotoxumab are human monoclonal antibodies against C. difficile toxins A and B, respectively.

Source: mdmag.com

CDC Issues New Vaccine Guidelines for Adults

February 6, 2017

While children in the U.S. are often required to be current on their vaccinations or receive a special waiver in order to attend public school, there is no requirement for adult vaccinations, despite several diseases that continue to present dangers. Public health officials have long struggled to bring adults in the U.S. up to date on vaccines.

Source: abcnews.go.com

Despite furor, branded Rx drug prices up nearly 11% last year

February 6, 2017

In the face of a national backlash on drug prices, a handful of drugmakers have pledged to limit their prices on branded prescription drugs to 10% or less this year. As it turns out, that is roughly how much they increased last year anyway.

Source: fiercepharma.com

Study: Drug costs lead many people to forgo prescriptions

February 7, 2017

About 45 million U.S. adults, or 18% of Americans over age 18, didn't fill a prescription last year because of high drug costs, according to nonprofit group Prescription Justice. The U.S. percentage of adults forgoing prescriptions because of cost is nine times higher than for adults in the United Kingdom (2%), where drugs are largely covered by national health insurance, Prescription Justice found in an analysis based on data from the Commonwealth Fund's 2016 International Health Policy Survey of Adults. The survey polled about 2,000 U.S. adults and nearly 27,000 adults overall.

Source: chaindrugreview.com

The A1C Blood Sugar Test May Be Less Accurate In African-Americans

February 7, 2017

A widely used blood test to measure blood-sugar trends can give imprecise results, depending on a person's race and other factors. This test means diabetes can sometimes be misdiagnosed or managed poorly.

Source: npr.org

New study finds Tamiflu 'cost-effective' in most pandemic scenarios

February 8, 2017

A new study released Wednesday indicates that Genentech's antiviral drug Tamiflu (oseltamivir) can reduce influenza infections and prevent deaths in a cost-saving manner under most pandemic scenarios.

Source: drugstorenews.com

RECALLS

Product Type	Product Description	Class	Code Information	Reason for Recall	Recalling Firm
Drugs	MegaJex Herbal Supplement, Maximum Formula for Men, Fast acting, Increase Stamina, 20 capsules, MS Bionics, Gardena, CA	Class I	All Lots exp. date 12/2019	Marketed without an Approved NDA/ANDA; product contains sildenafil and tadalafil which are active pharmaceutical ingredients in FDA approved drugs used to treat erectile dysfunction (ED)	MS Bionic 447 E Gardena Blvd Gardena, CA 90248-2913
Drugs	SLIMFIT X capsules, packaged in a 60-cont bottle	Class I	All lots and all expiration dates.	Marketed without an approved NDA/ANDA: Product contains undeclared sibutramine and desmethylsibutramine.	Jersey Shore Supplements, LLC 705 Brinley Ave Bradley Beach, NJ 07720-1054
Drugs	Lisinopril tablets, 5 mg, 1000-count bottle, Rx only, Manufactured for Accord Healthcare, Inc., Durham, NC 27703, NDC 16729-376-17	Class II	Lot # T04483, T04484, Exp 2/18; T06028, Exp 4/18; T08423, Exp 5/18	Failed tablet/capsule specification: missing break line on the 5mg tablet.	Accord Healthcare, Inc. 1009 Slater Rd Ste 210B Durham, NC 27703-8446
Drugs	Venlafaxine Hydrochloride extended release capsules, 37.5 mg, 30-count bottles, Rx Only, Manufactured for: Aurobindo Pharma USA, Inc. 2400 Route 130 North, Dayton, NJ 08810 Manufactured by: Aurobindo Pharma Limited Hyderabad-500 072 India, NDC 65862-527-30	Class II	Lot #: V13716010-A, Exp. 04/2018	Failed Tablet/Capsule Specifications: Some bottles contain punctured, and/or clumped/melted capsules.	Aurobindo Pharma USA Inc 666 Plainsboro Rd Ste 210 Plainsboro, NJ 08536-3004
Drugs	Mimvey Lo (estradiol and norethindrone acetate tablets USP), 0.5 mg/0.1 mg, 28 tablets per blister card (NDC 0093-5454-18), packaged in 3 blister cards per carton (NDC 0093-5454-62), Rx only, Manufactured By: Barr Laboratories, Inc., Pomona, NY 10970; Manufactured For: Teva Pharmaceuticals USA, Sellersville, PA 18960.	Class II	Lot # 33809881A, Exp 05/17; 33811151A, Exp 08/17	Failed Impurities/Degradation Specifications: out of specification test results for the norethindrone impurity.	Teva Pharmaceuticals USA 1090 Horsham Rd North Wales, PA 19454-1505
Drugs	Glipizide extended-release tablets, 2.5mg, 30-count bottle, Rx Only, Manufactured By Patheon Pharmaceuticals Inc Cincinnati OH 45237 USA, NDC 0591-0900-30, UPC 3-0591090030-4	Class II	Lot #: 3134201, 3134202, Exp. 06/30/17; 3134319, Exp. 05/31/17; 3135246, Exp. 07/31/17; 3135247, 3136781, Exp. 08/31/17; 3136782, Exp. 09/30/17; 3136903, 3136904, Exp.10/31/17; 3138250, Exp. 07/31/17; 3138968, Exp. 08/31/17; 3140000, Exp. 09/30/17	Failed Dissolution Specifications. Above out of specification for dissolution rate observed at the 10 hour testing point.	Actavis Inc 400 Interpace Pkwy Parsippany, NJ 07054-1120
Drugs	Clindamycin Phosphate and Benzoyl Peroxide Gel,	Class II	080806 (exp 12/16) 080844 (exp 12/16) 080963 (exp	Microbial Contamination of Non-Sterile Product;	L. Perrigo Company 515 Eastern Ave

Product Type	Product Description	Class	Code Information	Reason for Recall	Recalling Firm
	1.2%/5%, 45 g tubes, Rx Only, Manufactured by Perrigo, Yeruham, Israel, Distributed by Perrigo, Allegan, MI NDC 45802-736-84, UPC 345802736840		12/16) 080999 (exp 12/16) 0841 09 (exp 03/17 084197 (exp 03/17) 091 090 (exp 1 0/17) 092319 (exp 11/17) 092399 (exp 12/17) 092440 (exp 12/17)	small number of tubes may include the presence of mold on the cap	Allegan, MI 49010-9070
Drugs	Temozolomide Capsules, 100 mg, packaged in a) 5-count bottles (NDC 0378-5262-98), b) 14-count bottles (NDC 0378-5262-14), Rx only, Mylan Pharmaceuticals, Inc., Morgantown, WV 26505 USA.	Class II	LOT #: a) 2006895 and 2006896, Exp 02/18; b) 2006895, Exp 02/18	Failed Tablet/Capsule Specifications: customer complaints of broken or crushed capsules, resulting in loose powder in the bottle.	Mylan LLC. Road #156, Km. 58.8, Lot 24B Caguas, PR 00725
Drugs	Temozolomide Capsules, 140 mg, packaged in a) 5-count bottles (NDC 0378-5263-98), b) 14-count bottles (NDC 0378-5263-14), Rx only, Mylan Pharmaceuticals, Inc., Morgantown, WV 26505 USA.	Class II	LOT #: a) 2006903, Exp 02/18; b) 2006902, Exp 02/18	Failed Tablet/Capsule Specifications: customer complaints of broken or crushed capsules, resulting in loose powder in the bottle.	Mylan LLC. Road #156, Km. 58.8, Lot 24B Caguas, PR 00725
Drugs	Temozolomide Capsules, 180 mg, packaged in a) 5-count bottles (NDC 0378-5264-98), b) 14-count bottles (NDC 0378-5264-14), Rx only, Mylan Pharmaceuticals, Inc., Morgantown, WV 26505 USA.	Class II	LOT #: a) 2006915, Exp 02/18; b) 2006914, Exp 02/18	Failed Tablet/Capsule Specifications: customer complaints of broken or crushed capsules, resulting in loose powder in the bottle.	Mylan LLC. Road #156, Km. 58.8, Lot 24B Caguas, PR 00725
Drugs	Temozolomide Capsules, 250 mg, 5-count bottles, Rx only, Mylan Pharmaceuticals, Inc., Morgantown, WV 26505 USA, NDC 0378-5265-98.	Class II	LOT #: 2006912, Exp 02/18	Failed Tablet/Capsule Specifications: customer complaints of broken or crushed capsules, resulting in loose powder in the bottle.	Mylan LLC. Road #156, Km. 58.8, Lot 24B Caguas, PR 00725
Drugs	Furosemide Tablets USP, 20 mg, 1000 count bottles, Rx only, Roxane Laboratories, Inc., Columbus, Ohio 43216, NDC 0054-4297-31.	Class II	Lot# 660833A, Exp 08/31/18	Failed Tablet/Capsule Specifications: An unusually thick tablet was reported through a complaint.	Roxane Laboratories, Inc. 1809 Wilson Rd Columbus, OH 43228-9579
Drugs	Mesalamine, U.S.P. [CAS 89-57-6] Cambrex Charles City, Inc. Charles City, IA packaged in double lined PE liners inside Poly-lined cardboard drums. Net weight 40 kg	Class II	Code 1661911; Batch 1340; Exp. 03/17	Presence of Particulate Matter: Stainless steel in a chemical reactor dissolved into the API solution and was detected in the finished product.	Cambrex Charles City Inc 1205 11th St Charles City, IA 50616-3466
Drugs	MIDAZOLAM INJECTION, USP, *25 mg/5 mL, (5 mg/mL), 5 mL vials, 10 Vials per carton, Rx only, APP Pharmaceuticals, LLC Schaumburg, IL 60173 --- NDC 63323-412-05	Class II	Lot 6007327, exp. 01-2017; Lot 6007329, exp. 01-2017	Failed Impurities/Degradation Specifications	Fresenius Kabi USA, LLC 3 Corporate Dr Lake Zurich, IL 60047-8930
Drugs	Fluconazole Tablets, USP, 50 mg, a) 30 count (NDC 55111-143-30) and b) 100 count (NDC 55111-143-01)	Class II	a) 30 count C500221, exp 12/2016, C502342, exp 03/2017 b) 100 count C500221, exp 12/2016,	Failed Dissolution Specifications; 18 month stability time point	Dr. Reddy's Laboratories, Inc. 107 College Rd E Princeton, NJ 08540-

Product Type	Product Description	Class	Code Information	Reason for Recall	Recalling Firm
	bottles, Rx Only, Mfd. by: Dr. Reddy's Laboratories, Bachupally 500 090 India		C502342, exp 03/2017		6623
Drugs	Sun Pharma Carbidopa and Levodopa Tablets USP 25 mg/250 mg a) 100-count bottles (NDC 62756-519-88), b) 500-count bottles (NDC 62756-519-13) Rx Only, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512, Manufactured by: Sun Pharmaceutical Ind. Ltd. Halol-Baroda Highway, Halol-389 350 Gujarat, India.	Class II	a) JKP5530A Exp. 12/17, JKP3991A Exp. 11/17, JKR6535A Exp. 07/18 b) JKP5529A Exp. 11/17	Failed Dissolution Specifications	Sun Pharmaceutical Industries, Inc. 270 Prospect Plains Rd Cranbury, NJ 08512-3605
Drugs	Flucanazole Tablets, USP, 100 mg, a) 30 count (NDC 55111-144-30) and b) 100 count (NDC 55111-144-01) bottles, Rx Only, Mfd. by: Dr. Reddy's Laboratories, Bachupally 500 090 India	Class II	a) 30 count C500224, exp 12/2016, C500846, exp 01/2017 b) 100 count C500224, exp 12/2016, exp 12/2016, C501608, exp 02/2017 and C503655, exp 04/2017	Failed Dissolution Specifications; 18 month stability time point	Dr. Reddy's Laboratories, Inc. 107 College Rd E Princeton, NJ 08540-6623
Drugs	Flucanazole Tablets, USP, 150 mg, 12x1 Blister cards, Rx Only, Mfd. by: Dr. Reddy's Laboratories, Bachupally 500 090 India --- NDC 55111-145-12	Class II	C500222, C500515, and C500517, exp 12/2016, C502343, exp 03/2017	Failed Dissolution Specifications; 18 month stability time point	Dr. Reddy's Laboratories, Inc. 107 College Rd E Princeton, NJ 08540-6623
Drugs	Flucanazole Tablets, USP, 200 mg, a) 30 count (NDC 55111-146-30) and b) 100 count (NDC 55111-146-01) bottles, Rx Only, Mfd. by: Dr. Reddy's Laboratories, Bachupally 500 090 India	Class II	a) 30 count C500228, exp 12/2016, C500848 and C500850, exp 01/2017 C503651 and C503653, exp 04/2017, b) 100 count C500226, exp 12/2016, C500848, C500850, exp 01/2017, C503649 and C503653, exp 04/2017	Failed Dissolution Specifications; 18 month stability time point	Dr. Reddy's Laboratories, Inc. 107 College Rd E Princeton, NJ 08540-6623
Drugs	Nystatin Oral Suspension, USP 100,000 units per mL, a) 2 fl. oz. (60 mL), 24 bottles per case (NDC 66689-008-02), b) 16 fl. oz. (237 mL), 12 bottles per case (NDC 66689-008-16), Rx only, Manufactured by VistaPharm, Largo, FL 33771	Class II	a) Lot No. 422600 (Exp. 10/17), 420000 (Exp. 09/17), 416100 (Exp. 08/17), 417400 (Exp. 09/17) b) Lot No. 424200 (Exp. 10/17), 415500 (Exp. 03/18)	CGMP Deviations: Purified water used to manufacture the drug products may have been contaminated with Burkholderia cepacia	VistaPharm, Inc. 7265 Ulmertont Rd Largo, FL 33771-4809
Drugs	Hydrocodone Bitartrate and Acetaminophen Oral Solution, 7.5 mg/325 mg per 15 mL C-II, a) 4 fl.oz. (120 mL), 12 bottles per case (NDC 66689-023-04), b) 16 fl.oz. (473 mL), 12 bottles per case (NDC 66689-023-16), c) 50 unit dose cups of 15 mL per case, (NDC No. 66689-023-50), Rx only, Manufactured by VistaPharm, Largo, FL 33771	Class II	a). Lot No. 419000 (Exp. 03/17) b.) Lot No. 419800 (Exp. 03/17), 429100 (Exp. 06/17) c). Lot No. 418200 (Exp. 03/17), 430100 (Exp. 06/17), 423800 (Exp. 04/17), 413100 (Exp. 02/17), 410700 (Exp. 01/17)	CGMP Deviations: Purified water used to manufacture the drug products may have been contaminated with Burkholderia cepacia.	VistaPharm, Inc. 7265 Ulmertont Rd Largo, FL 33771-4809

Product Type	Product Description	Class	Code Information	Reason for Recall	Recalling Firm
Drugs	Metoclopramide Oral Solution, USP 10 mg/ 10 mL, 50 unit dose cups of 10 mL per case, Rx only, Manufactured by VistaPharm, Largo, FL 33771, NDC No. 66689-031-50.	Class II	Lot No. 428700 (Exp. 11/17), 409500 (Exp.06/17)	CGMP Deviations: Purified water used to manufacture the drug products may have been contaminated with Burkholderia cepacia.	VistaPharm, Inc. 7265 Ulmerton Rd Largo, FL 33771-4809
Drugs	Phenytoin Oral Suspension, USP 100 mg/ 4 mL, 50 unit dose cups of 4 mL per case., Rx only, Manufactured by VistaPharm, Largo, FL 33771, NDC No. 66689-036-50.	Class II	Lot No. 428700 (Exp. 11/17), 409500 (Exp. 06/17)	CGMP Deviations: Purified water used to manufacture the drug products may have been contaminated with Burkholderia cepacia.	VistaPharm, Inc. 7265 Ulmerton Rd Largo, FL 33771-4809
Drugs	Nystatin Oral Suspension, USP 500,000 Units/5 mL, a). 50 unit dose cups of 5 mL per case (NDC No. 66689-037-50), b). 100 unit dose cups of 5 mL per case (NDC 66689-037-99), Rx only, Manufactured by VistaPharm, Largo, FL 33771.	Class II	a). Lot No. 428900, 425600 (Exp. 05/17); 421200 (Exp. 04/17), 413600 (Exp. 02/17), 411500 (Exp. 01/17), 417200 (Exp. 03/17) b). Lot No. 429300 (Exp. 06/17), 426500 (Exp. 05/17), 420600 (Exp. 03/17), 417000 (Exp.03/17), 412900 (Exp. 01/17), 409900 (Exp. 01/17)	CGMP Deviations: Purified water used to manufacture the drug products may have been contaminated with Burkholderia cepacia.	VistaPharm, Inc. 7265 Ulmerton Rd Largo, FL 33771-4809
Drugs	Lactulose Solution, USP 20 g/30 mL, 50 unit dose cups of 30 mL per case, Rx only, Manufactured by VistaPharm, Largo, FL 33771, NDC No. 66689-038-50.	Class II	Lot No. 422800 (1Exp. 0/17), 430500 (Exp. 12/17), 424000 (Exp. 10/17), 412500 (Exp. 07/17), 405500 (Exp. 05/17), 414900 (Exp. 09/17)	CGMP Deviations: Purified water used to manufacture the drug products may have been contaminated with Burkholderia cepacia.	VistaPharm, Inc. 7265 Ulmerton Rd Largo, FL 33771-4809
Drugs	Lactulose Solution, USP 10 g/15 mL, 50 unit dose cups of 15 mL per case, Rx only, Manufactured by VistaPharm, Largo, FL 33771, NDC No. 66689-039-50.	Class II	a). Lot No. 728300 (Exp. 11/17), 423200 (Exp. 10/17), 418400 (Exp. 09/17), 411100 (Exp. 07/17), 406500 (Exp. 06/17)	CGMP Deviations: Purified water used to manufacture the drug products may have been contaminated with Burkholderia cepacia.	VistaPharm, Inc. 7265 Ulmerton Rd Largo, FL 33771-4809
Drugs	Oxycodone Hydrochloride Oral Solution, USP 5 mg/5 mL, a). 5 mL, 50 unit dose cups of 5 mL per case (NDC No. 66689-401-50), b). 500 mL, 12 bottles per case (NDC No. 66689-403-16), Rx only, Manufactured by VistaPharm, Largo, FL 33771.	Class II	a). Lot No. 427900, 426700 (Exp. 11/17), 424800, 423600 (Exp. 10/17), 420800 (09/17), 416300 (08/17), 407700, 407300 (Exp. 06/17), 405900, 403900 (Exp. 05/17) b). Lot No. 426900 (Exp. 11/17), 404700 (Exp. 05/17), 390200 (Exp. 02/17)	CGMP Deviations: Purified water used to manufacture the drug products may have been contaminated with Burkholderia cepacia	VistaPharm, Inc. 7265 Ulmerton Rd Largo, FL 33771-4809
Drugs	Methadone Hydrochloride Oral Concentrate, USP 10 mg/mL C-II, a.) 1 fl. oz. (30 mL), 12 bottles per case (NDC No. 66689-695-30), b). 1 liter (1000 mL), 4 bottles per case, (NDC No. 66689-695-79), Rx only, Manufactured by VistaPharm, Largo, FL 33771.	Class II	a). Lot No. 416600 (Exp. 09/17) b). Lot No.449100 , 447500 (Exp. 04/18), 421800 (Exp. 10/17), 418600 (Exp. 09/17), 408700 (Exp. 06/17), 411900 (Exp. 07/17), 413800 (Exp. 08/17), 416500 (Exp. 09/17), 408500 (Exp. 06/17), 389800 (Exp. 01/17), 429900 (Exp. 12/17),	CGMP Deviations: Purified water used to manufacture the drug products may have been contaminated with Burkholderia cepacia	VistaPharm, Inc. 7265 Ulmerton Rd Largo, FL 33771-4809

Product Type	Product Description	Class	Code Information	Reason for Recall	Recalling Firm
			406300, 406100 (Exp. 05/17), 429700 (Exp. 12/17), 427300, 427100, 425900 (11/17)		
Drugs	Methadone Hydrochloride Oral Concentrate, USP 10 mg/mL C-II (Sugar Free), 1 liter (1000 mL), 4 bottles per case, Rx only, Manufactured by VistaPharm, Largo, FL 33771, NDC No. 66689-695-79.	Class II	Lot No. 423000 (Exp. 10/17), 415100 (Exp. 08/17)	CGMP Deviations: Purified water used to manufacture the drug products may have been contaminated with Burkholderia cepacia.	VistaPharm, Inc. 7265 Ulmerton Rd Largo, FL 33771-4809
Drugs	Methadone Hydrochloride Oral Concentrate, USP 5 mg/5 mL C-II, 500 mL, 6 bottles per case, Rx only, Manufactured by VistaPharm, Largo, FL 33771, NDC No. 66689-711-16.	Class II	Lot No. 388700 (Exp. 01/17)	CGMP Deviations: Purified water used to manufacture the drug products may have been contaminated with Burkholderia cepacia	VistaPharm, Inc. 7265 Ulmerton Rd Largo, FL 33771-4809
Drugs	Potassium Chloride Oral Solution, USP, 10%, 20 mEq per 15 mL, packaged in 15 mL unit dose cups (NDC 66689-047-01), 50 unit dose cups per case (NDC 66689-047-50), Rx only, Xact Dose, Manufactured by VistaPharm, Largo, FL 33771.	Class II	Lot #'s: 437600, Exp 07/17; 447100, Exp 10/17	Defective Container: Leakage of unit dose cups that may occur at the seal.	VistaPharm, Inc. 7265 Ulmerton Rd Largo, FL 33771-4809
Drugs	HCG (Chorionic Gonadotropin Lyophilized) II, 1000 unit vial, Rx only, Prepared by Town & Country, Compounding & Consultation Services, 106 Prospect St - 1st FL, Ridgewood, NJ 07459	Class III	Lot #: 05272016@17	Subpotent Drug: due to failed potency results of 74% (spec. 80-125%).	Town and Country Compounding and Consultation Services, LLC 106 Prospect St Ste 2 Ridgewood, NJ 07450-4433
Drugs	Risendronate Sodium Delayed-release Tablets, 35 mg, Once-a-Week, 1 tablet per blister (NDC 0093-5509-19), packaged in 4 blisters per carton (NDC 0093-5509-44), Rx only, TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454.	Class III	Lot # 34027040A; Exp 10/17	Failed Dissolution Specifications	Teva Pharmaceuticals USA 1090 Horsham Rd North Wales, PA 19454-1505
Drugs	Pentasa (mesalamine) Controlled-Release Capsules, 250 mg, 240 count bottle, Rx only, Manufactured for Shire US Inc., Lexington, MA --- NDC 54092-189-81	Class III	Lot Number AE7363A, exp 06/30/2019	Presence of Foreign Tablets/Capsules; 500 mg capsules were found in bottles labeled to contain 250 mg capsules	Shire PLC 300 Shire Way Lexington, MA 02421-2101
Drugs	Donepezil Hydrochloride Tablets, 10 mg, packaged in a) 30-count bottles (NDC 0781-5275-31) and b) 1000-count bottles (NDC 0781-5275-10), Rx only,	Class III	Lot #: a) FJ6599, Exp 05/17 and b) FJ6600, Exp 05/17	Subpotent Drug: out of specification results for assay test.	Sandoz Inc 100 College Rd W Princeton, NJ 08540-6604

Product Type	Product Description	Class	Code Information	Reason for Recall	Recalling Firm
	Manufactured in India by Sandoz Private Ltd for Sandoz Inc., Princeton, NJ 08540.				
Drugs	Novacort Gel Sample Packets (2% hydrocortisone acetate, 1% pramoxine HCl), 10-count Carton of 1.0 g sample packets), NDC 69646-704-38 (10 ct. Carton of 1gm samples) / NDC 69646-704-01 (Individual 1gm Samples within Carton), Rx Only, Novum Pharma LLC, Chicago, IL 60654	Class III	Lot: 8249 - Exp. Date: 03/18 Lot: 8250 - Exp. Date: 06/18	Subpotent Drug: Out of specification result for pramoxine hydrochloride	Novum Pharma, LLC Suite 670 640 N. Lasalle Street Chicago, IL 60654
Drugs	Azelastine Hydrochloride Nasal Solution (Nasal Spray), 0.1% (137 mcg per spray), packaged in 30 mL bottles, Rx only, Distributed by: West-Ward Pharmaceuticals Corp., Eatontown, NJ 07724, NDC 0054-0293-99	Class III	Lot # 659365A, Exp 3/31/2018	Defective Delivery System: out of specification result for droplet size distribution at the d90 measurement testing during the 6 month time point	Roxane Laboratories, Inc. 1809 Wilson Rd Columbus, OH 43228-9579
Drugs	Albuterol Sulfate Inhalation Solution, USP, 0.021% (0.63 mg / 3 mL), 3mL Vials, Rx only, Mfd. for Watson Laboratories Inc., Corona, CA 92880 USA, Mfd. by Cipla Ltd. Verna, Goa India, NDC 0591-3467-53	Class III	Lot #: GA51265, Ex[p. Jan-2017, GA51454, GA51553, GA51583, Exp. Feb-2017, GA51598, GA51724, GA51725, GA51749, Exp. Mar-2017	Failed Impurities/Degradation Specifications: Product is out of specification for a known degradant.	Actavis Inc 400 Interpace Pkwy Parsippany, NJ 07054-1120
Drugs	DEXAMETHASONE ELIXIR, USP, 0.5 mg/5 mL, 8 fl.oz., Rx only, Manufactured for: QUALITEST PHARMACEUTICALS, HUNTSVILLE, AL, NDC 0603-1147-56	Class III	Lot # 0000007104; Exp 05/17	Failed Impurities/Degradation Specifications	Vintage Pharmaceuticals LLC dba Qualitest Pharmaceuticals 130 Vintage Dr Ne Huntsville, AL 35811-8216
Drugs	buPROPion Hydrochloride Extended-release Tablets, USP (SR), 150 mg, a) 60 (NDC 47335-737-86), b) 100 (NDC 47335-737-88) and c) 500 (NDC 47335-737-13) count bottles, Rx only, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512, Manufactured by: Sun Pharmaceutical Ind. Ltd., Halol-Baroda Highway, Halol-389 350, Gujarat, India	Class III	a) 60 count JKP1184A , exp 2/17; JKP1576A, JKP2517A, JKP2527A, exp 04/17; JKP2768A exp 06/17; KP3895A, JKP4051A, exp 08/17; JKP4052A, JKP4605A exp 09/17 b) 100 count JKP0702A exp 01/17; JKP1186A exp 02/17; JKP2766A, exp 05/17; JKP3368A, JKP3369A exp 06/17; JKP3419A, JKP3420A exp 07/17; JKP4056A, JKP4603A, exp 09/17 c) 500 count JKP0093A, JKP0094A, JKP0703A, JKP0704A, exp 01/17; JKP1182A, JKP1183A, JKP1185A, exp 02/17;	Failed Dissolution Specifications; 18 month stability time point	Sun Pharmaceutical Industries, Inc. 270 Prospect Plains Rd Cranbury, NJ 08512-3605

Product Type	Product Description	Class	Code Information	Reason for Recall	Recalling Firm
			JKP1187A, JKP1188A, JKP1577A, JKP1578A, JKP2528A, exp 04/17; JKP2764A, JKP2765A, JKP2767A, exp 05/17; JKP3370A, JKP3371A, exp 06/17; JKP3372A, JKP3417A, JKP3418A, JKP3421A, JKP3889A, exp 07/17; JKP3892A, JKP3893A, JKP3894A, exp 08/17; JKP4053A, JKP4054A, JKP4055A, JKP4057A, JKP4600A, JKP4601A, JKP4602A, exp 09/17; JKP4742A, JKP4743A, exp 10/17		
Drugs	buPROPion Hydrochloride Extended-release Tablets, USP (SR), 200 mg, 60 count bottles, Rx only, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512, Manufactured by: Sun Pharmaceutical Ind. Ltd., Halol-Baroda Highway, Halol-389 350, Gujarat, India NDC 47335-0738-86	Class III	JKP0905A 04/17	Failed Dissolution Specifications; 18 month stability time point	Sun Pharmaceutical Industries, Inc. 270 Prospect Plains Rd Cranbury, NJ 08512-3605
Drugs	Finasteride Tablets, USP 5 mg, 90-count bottles, Rx only, Manufactured for : Camber Pharmaceuticals, Inc. Piscataway, NJ 08854 By: Hetero Hetero Labs, Unit V Polepally, Jadcheria, Mahaboob Nagar - 509 301, India Limited NDC 31722-525-90	Class III	Lot #: FIN16002, Exp. 03/2018	Failed Tablet/Capsule Specification: Tablets were found to be twice the thickness in one lot of product.	Hetero Drugs Ltd. - Unit 1 Plot Nos. 213, 214, 255 Bonthapally Village, Jinnaram Mandal Medak District
Drugs	Olanzapine tablets, USP, 2.5 mg, packaged in a 30-count bottle, Rx only, Mfd: By: Dr. Reddy's Laboratories Limited, Bachupally, India, NDC 55111-163-30	Class III	C500202	Failed impurities/degradation specifications: due to out-of-specification result for the Related Substance Compound C (Impurity 6 - N-Oxide at the 18 month stability station.	Dr. Reddy's Laboratories, Inc. 107 College Rd E Princeton, NJ 08540-6623
Drugs	Aripiprazole Tablets, 2 mg, 30-count bottle, Rx only, Manufactured by: Apotex Inc., Toronto, Ontario, Canada, M9L 1T9; Manufactured for: Apotex Corp., Weston, Florida 33326, NDC 60505-3075-3.	Class III	Lot #: MJ7746, Exp 04/17	Superpotent Drug: Product may not meet specifications throughout shelf life.	Apotex Inc. 150 Signet Drive Toronto
Drugs	Pantoprazole Sodium for Injection, 40mg per vial, Single-dose vial, Rx only, Mfd. in India for: Auromedics Pharma LLC 6 Wheeling Road, Dayton, NJ 08810, NDC 55150-202-00	Class III	Lot #: CPO160028, Exp. June 2018	Discoloration: Some vials were found to contain powder with a yellowish-brownish appearance.	Aurobindo Pharma USA Inc 666 Plainsboro Rd Ste 210 Plainsboro, NJ 08536-3004
Drugs	Taclonex (calcipotriene and	Class	Lot #: (a): EK9025, Exp.	Labeling: Incorrect or	LEO PHARMA INC

Product Type	Product Description	Class	Code Information	Reason for Recall	Recalling Firm
	betamethasone dipropionate) Topical Suspension, 0.005%/0.064%, packaged in (a) 60 g (NDC 50222-501-06), and (b)120 g (50222-501-66) tubes, Rx Only, Manufactured by: LEO Laboratories Ltd., 285 Cashel Road, Dublin 12 Ireland, Distributed by: LEO Pharma Inc. 1 Sylvan Way, Parsippany, NJ 07054.	III	2/28/2017; EL1057, Exp. 3/31/2017; EL4637, Exp. 6/30/2017; EM0825B, Exp. 11/30/2017; EM3992, Exp. 1/31/2019; A22902, Exp. 5/31/2019; A31838, Exp. 9/30/2019 Lot #:EK7007A, EK7007AA, Exp. 1/31/2017; EL2024, EL2979, Exp. 5/31/2017; EL8069, Exp. 10/31/2017; EA20780AA, Exp. 5/31/2019.	missing package insert: the affected product was packaged with an out-of-date package insert (PI) dated February 2014.	7 Giralda Farms Madison, NJ 07940-1051

*Please refer to FDA website for further information; <http://www.fda.gov/Safety/Recalls/EnforcementReports/default.htm>

CURRENT DRUG SHORTAGES

Sodium Phosphate Injection

January 20, 2017

Reason for the Shortage

- American Regent has sodium phosphate injection on shortage due to manufacturing delay.
- Fresenius Kabi states the reason for the shortage was increased demand.
- Hospira had sodium phosphate injection on shortage due to manufacturing delay.

Estimated Resupply Dates

- American Regent has sodium phosphate 3 mmol/mL 5 mL, 15 mL, and 50 mL vials on back order and the company cannot estimate a release date.¹
- Fresenius Kabi has imported Glycophos available with an expiration date of <2 months.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=770>

Penicillin G Procaine Injection

January 20, 2017

Reason for the Shortage

- Pfizer has penicillin G procaine on shortage due to manufacturing delays.
- Pfizer is the sole supplier of penicillin G procaine.

Estimated Resupply Dates

- Pfizer has penicillin G procaine 600,000 unit/mL 1 mL and 2 mL vials on back order and the company estimates a release date of early-April 2017.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1238>

Penicillin G Benzathine

January 20, 2017

Reason for the Shortage

- Pfizer states the shortage is due to a delay in the manufacturing process.

Estimated Resupply Dates

- Pfizer has Bicillin L-A 600,000 unit/ 1 mL syringes, 1,200,000 unit/ 2 mL syringes, and 2,400,000 unit/ 4 mL syringes on allocation.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1232>

Ciprofloxacin Oral Suspension

January 20, 2017

Reason for the Shortage

- Lupin did not provide a reason for the shortage.

Estimated Resupply Dates

- Lupin has ciprofloxacin oral suspension on long-term back order and the company cannot estimate a release date.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1247>

Cefotaxime Injection

January 24, 2017

Reason for the Shortage

- Hospira has discontinued Claforan. Sanofi-Aventis manufactured Claforan for Hospira and is no longer making the product.
- Baxter discontinued Claforan in late-2015. West-Ward has cefotaxime on shortage due to increased demand.

Estimated Resupply Dates

- West-Ward has cefotaxime 500 mg, 1 gram, 2 gram, and 10 gram vials on long-term back order and the company cannot estimate a release date.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=826>

Amikacin Injection

January 24, 2017

Reason for the Shortage

- West-Ward launched amikacin injection in 2 mL and 4 mL vials in December 2015. West-Ward did not provide a reason for the shortage.
- Teva has amikacin available.
- Heritage has amikacin available.
- Fresenius Kabi has amikacin available.

Estimated Resupply Dates

- West-Ward has amikacin 250 mg/mL 2 mL and 4 mL vials on back order and the company cannot estimate a release date.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=501>

Sincalide Injection

January 25, 2017

Reason for the Shortage

- Bracco Diagnostics has Kinevac injection on shortage due to a supply disruption.
- There are no approved alternatives to Kinevac for the labeled indications.

Estimated Resupply Dates

- Bracco has Kinevac on partial allocation.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1032>

Multiple Vitamins for Infusion

25 January 25, 2017

Reason for the Shortage

- Hospira states the shortage is due to manufacturing delays.
- Baxter has all presentations fully available at this time.

Estimated Resupply Dates

- Hospira has MVI Adult 5 mL Dual vials and MVI Adult 50 mL Dual vials are on back order and the company estimates a release date of 1st quarter 2017.
- Hospira has MVI pediatric 5 mL vials on back order and the company estimates a release date in 2nd quarter 2017.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=831>

Gadoteridol Injection

25 January 25, 2017

Reason for the Shortage

- Bracco diagnostics could not provide a reason for the shortage.

Estimated Resupply Dates

- Bracco diagnostics has ProHance 15 mL vials and 17 mL prefilled syringes on allocation.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1237>

Estradiol Valerate Injection

January 25, 2017

Reason for the Shortage

- Par states the reason for the shortage is manufacturing delay.
- Perrigo states the reason for the shortage is manufacturing issues.

Estimated Resupply Dates

- Par Sterile Products has Delestrogen 10 mg/mL 5 mL vials, 20 mg/mL 5 mL vials, and 40 mg/mL 5 mL vials on back order and the company estimates a release date of late-March 2017.
- Perrigo has estradiol valerate 40 mg/mL 5 mL vials on intermittent back order and the company is releasing product as it becomes available.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1186>

Asparaginase Erwinia chrysanthemi

January 25, 2017

Reason for the Shortage

- Jazz Pharmaceuticals had Erwinaze on shortage due to manufacturing issues.

Estimated Resupply Dates

- Jazz Pharmaceuticals has Erwinaze available.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1252>

Diltiazem Injection

January 26, 2017

Reason for the Shortage

- Akorn states the reason for the shortage is increased demand due to market conditions.
- Pfizer states the reasons for the shortage was manufacturing delays and increases in demand.
- West-Ward has diltiazem injection on shortage due to manufacturing delays caused by increased demand due to current market conditions.

Estimated Resupply Dates

- Akorn has diltiazem 5 mg/mL 10 mL vials and 25 mL vials in 10 count available but with short-expiration dating of 3rd quarter 2017.
- West-Ward has diltiazem 5 mg/mL 25 mL vials on allocation. The 10 mL vials have an expiration date of November 2017 or earlier.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=217>

Alcohol Dehydrated Injection (Ethanol)

January 26, 2017

Reason for the Shortage

- Akorn states the back order was due to manufacturing delays.

Estimated Resupply Dates

- Akorn has dehydrated alcohol 5 mL vials available in limited supply.
- American Regent has dehydrated alcohol 1 mL ampules on back order and the company cannot estimate a release date.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=778>

Mupirocin Calcium 2% Nasal Ointment

January 27, 2017

Reason for the Shortage

- GlaxoSmithKline states the shortage is due to manufacturing issues.
- GlaxoSmithKline is looking for an alternative supply source

Estimated Resupply Dates

- GlaxoSmithKline has Bactroban Nasal 2% Ointment in 1 gram tubes on back order and the company cannot estimate a release date

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1094>

Mupirocin Calcium 2% Cream

January 27, 2017

Reason for the Shortage

- GlaxoSmithKline is looking for an alternative supply source.

- Prasco discontinued mupirocin calcium 2% cream in February 2016.

Estimated Resupply Dates

- GlaxoSmithKline has Bactroban 2% cream in 15 gram and 30 gram sizes on back order and the company cannot estimate a release date.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1206>

Morrhuate Sodium Injection

January 27, 2017

Reason for the Shortage

- American Regent has morrhuate sodium injection on shortage due to manufacturing delays.

Estimated Resupply Dates

- American Regent has morrhuate sodium 50 mg/mL 30 mL vials on back order and the company cannot estimate a release date.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=903>

Morphine Injections

January 27, 2017

Reason for the Shortage

- Astramorph injection has been unavailable since 2012. Fresenius Kabi changed manufacturing sites and cannot estimate if Astramorph will return.
- Pfizer states the shortage is due to manufacturing delays.
- West-Ward launched several new morphine sulfate products in late-September 2015. They are not actively marketing the 15 mg/mL 1mL vials.

Estimated Resupply Dates

- Pfizer has morphine 1 mg/mL 10 mL preservative-free vials and 4 mg/mL 1 mL iSecure syringes on back order and the company estimates a release date of 1st quarter 2017. They have morphine 25 mg/mL 4 mL and 10 mL ADD-vantage vials on back order and the company cannot estimate a release date.
- West-Ward has Infumorph 10 mg/mL 20 mL preservative-free vials on back order and the company estimates a release date of February to March 2017.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=664>

Methyldopate Injection

January 27, 2017

Reason for the Shortage

- American Regent has methyldopate injection on shortage due to manufacturing delays.
- There are no other suppliers of methyldopate injection.

Estimated Resupply Dates

- American Regent has methyldopate injection on back order and the company cannot estimate a release date.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=844>

Melphalan Tablets

January 27, 2017

Reason for the Shortage

- Apo-Pharma did not provide a reason for the Alkeran tablets shortage.

Estimated Resupply Dates

- Apo-Pharma has Alkeran oral tablets available.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1261>

Electrolyte Concentrate

January 27, 2017

Reason for the Shortage

- American Regent has Nutrilite and Nutrilite II on back order due to manufacturing delays.

Estimated Resupply Dates

- American Regent has Nutrilite and Nutrilite II presentations on back order and the company cannot estimate a release date.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1054>

Dexpanthenol Injection

January 27, 2017

Reason for the Shortage

- American Regent has dexpanthenol injection on shortage due to manufacturing delays. There are no other suppliers of dexpanthenol injection.

Estimated Resupply Dates

- American Regent has dexpanthenol injection on long-term back order and the company cannot estimate a release date.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1103>

Atropine Sulfate Injection

January 27, 2017

Reason for the Shortage

- Pfizer states the shortage was due to manufacturing delays.

Estimated Resupply Dates

- Pfizer has atropine 0.05 mg/mL 5 mL Ansyr syringes on back order and the company cannot estimate a release date.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=814>

Atropine Sulfate Injection

January 27, 2017

Reason for the Shortage

- Pfizer states the shortage was due to manufacturing delays.

Estimated Resupply Dates

- Pfizer has atropine 0.05 mg/mL 5 mL Ansyr syringes on back order and the company cannot estimate a release date.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=814>

Ketorolac Tromethamine Injection

January 30, 2017

Reason for the Shortage

- BD Rx has ketorolac injection available. BD RX is now part of Fresenius Kabi.
- Fresenius Kabi has ketorolac injection available.
- Pfizer has ketorolac injection available.
- Sagent states the reason for the shortage is manufacturing delay.
- West-Ward is not actively marketing ketorolac injection.
- Ben Venue closed its plant in Bedford, Ohio in July 2014.
- FDA imposed an import ban in mid-2013 on several Wockhardt products including ketorolac.
- Sprix Nasal Spray is not affected by this shortage.

Estimated Resupply Dates

- Sagent has ketorolac 15 mg/mL 1 mL vials, 30 mg/mL 1 mL vials, and 30 mg/mL 2 mL vials for intramuscular injection on back order and the company estimates a release date of February 2017.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=593>

Erythromycin Lactobionate Injection

January 30, 2017

Reason for the Shortage

- Pfizer (Hospira) has Erythrocin on shortage due to manufacturing delays.

Estimated Resupply Dates

- Pfizer (Hospira) has Erythrocin 500 mg ADD-Vantage vials on back order and the company estimates a release date of April 2017.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=546>

5% Lidocaine and 7.5% Dextrose Injection

January 30, 2017

Reason for the Shortage

- Pfizer has 5% lidocaine and 7.5% dextrose 2 mL ampules on shortage due to manufacturing delays.
- Pfizer is the sole supplier of this combination.

Estimated Resupply Dates

- Pfizer has 5% lidocaine and 7.5% dextrose 2 mL ampules on long-term back order and the company estimates a release date of 2nd quarter 2018.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1245>

Yellow Fever Vaccine Injection

January 31, 2017

Reason for the Shortage

- Sanofi Pasteur could not provide a reason for the shortage of YF-Vax.
- There are no other suppliers of yellow fever vaccine.

Estimated Resupply Dates

- Sanofi Pasteur has YF-Vax multi-dose vials and single dose vials available in limited supply.
- Customers can call Sanofi Pasteur to order product for patients traveling in the next 30 days.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=383>

Vecuronium Bromide Injection

January 31, 2017

Reason for the Shortage

- Pfizer has vecuronium on shortage due to manufacturing delays.
- Teva is not actively marketing vecuronium.
- Pfizer sold vecuronium injection to Mylan Institutional in December 2013.
- Ben Venue has stopped production in its plant in Bedford, Ohio and closed in 2014.
- Caraco will not provide availability information at this time.
- Sagent is not marketing vecuronium 10 mg and 20 mg vials.

Estimated Resupply Dates

- Pfizer has vecuronium 10 mg and 20 m vials available in limited supply.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=490>

Tetanus and Diphtheria Toxoids Adsorbed

January 31, 2017

Reason for the Shortage

- Grifols has tetanus and diphtheria toxoids adsorbed (Td) available.
- Sanofi Pasteur has Tenivac on shortage due to manufacturing delays.
- Adult tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccines are not affected by this shortage.
- Pediatric diphtheria and tetanus toxoids adsorbed (DT) and diphtheria and tetanus toxoids and acellular pertussis vaccines (DTaP) are not affected by this shortage.

Estimated Resupply Dates

- Sanofi Pasteur has Tenivac on back order and the company estimates a release date in June 2017.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1260>

Methylphenidate Hydrochloride Chewable Tablets

January 31, 2017

Reason for the Shortage

- Shionogi Pharma has Methylin chewable tablets on shortage due to manufacturing issues.
- Gavis launched methylphenidate chewable tablets in April 2015.

Estimated Resupply Dates

- Shionogi Pharma has all Methylin chewable tablets on long-term back order and the company cannot estimate a release date.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1163>

Meningococcal Vaccines

January 31, 2017

Reason for the Shortage

- Sanofi Pasteur has Menomune and Menactra available.
- GlaxoSmithKline acquired Bexsero and Menveo from Novartis Vaccines and Diagnostics in 2015.
- GlaxoSmithKline did not provide a reason for the shortage.
- Pfizer has Trumenba available.

Estimated Resupply Dates

- GlaxoSmithKline has Bexsero prefilled syringes in 10 count on intermittent back order and the company is allocating supplies as they become available.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1192>

Haloperidol Decanoate Injection

January 31, 2017

Reason for the Shortage

- Teva products are on shortage due to manufacturing delays.
- West-Ward Pharmaceuticals' parent company, Hikma Pharmaceuticals, acquired haloperidol decanoate injection from Bedford in July 2014. West-Ward is not actively marketing haloperidol decanoate injection at this time. .
- Fresenius Kabi has haloperidol decanoate on shortage due to short-term manufacturing delays.

Estimated Resupply Dates

- Fresenius Kabi has haloperidol decanoate 50 mg/mL 1 mL vials on back order and the company estimates a release date of 1st quarter 2017. Haloperidol decanoate 50 mg/mL 5 mL vials have a short expiration date (< 8 months).
- Teva has all haloperidol decanoate presentations on long-term back order and the company estimates a release date in 1st quarter 2017.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=526>

Cefuroxime Sodium Injection

January 31, 2017

Reason for the Shortage

- Teligent has Zinacef on shortage due to increased demand.
- West-Ward did not provide a reason for the cefuroxime injection shortage.

Estimated Resupply Dates

- Sagent has cefuroxime 7.5 gram vials on back order and the company cannot estimate a release date.
- Teligent has Zinacef 1.5 gram vials on back order and the company estimates a release date of 1st quarter 2017. The 7.5 gram vials are on back order and the company cannot estimate a release date.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=990>

Ceftazidime Injection

January 31, 2017

Reason for the Shortage

- IGI Laboratories changed its name to Teligent in late-October 2015.
- Covis divested Fortaz injection to IGI Laboratories in October 2015.
- Pfizer had Tazicef on shortage due to manufacturing delays.
- Sagent has ceftazidime injection on shortage due to manufacturing delays.
- Sandoz discontinued ceftazidime 1 gram and 2 gram vials in 2015.
- BBraun has ceftazidime on allocation due to increased demand.

Estimated Resupply Dates

- BBraun has ceftazidime 1 gram/50 mL and 2 gram/50 mL premixed bags on allocation.
- Teligent has Fortaz 500 mg, 2 gram, and 6 gram vials on back order and the company estimates a release date of 1st quarter 2017 for the 500 mg vials, February 2017 for the 2 gram vials, and the company cannot estimate a release date for the 6 gram vials. The 1 gram/50 mL and 2 gram/50 mL premixed bags are on back order and the company estimates a release date of February 2017.
- Sagent has ceftazidime 2 gram and 6 gram vials on back order and the company estimates a release date of February 2017. The 1 gram vials are on allocation.
- Pfizer has Tazicef 1 gram ADD-Vantage vials available in limited supply. The 1 gram and 2 gram vials are on back order and the company estimates a release date of mid-February 2017. Tazicef 2 gram ADD-Vantage vials are on back order and the company estimates a release date of April 2017. Tazicef 6 gram vials are on back order and the company estimates a release date of late-February 2017.
- WG Critical Care has ceftazidime 2 gram and 6 gram vials on back order and the company estimates a release date of early-March 2017 for the 6 gram vials and cannot estimate a release date for the 2 gram vials.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=869>

Cefotetan Disodium Injection

January 31, 2017

Reason for the Shortage

- BBraun had cefotetan on allocation due to current market conditions.
- Fresenius Kabi states the reason for the shortage is manufacturing delay.
- Teligent received FDA approval for Cefotan in 2015. Teligent launched Cefotan in March 2016.

Estimated Resupply Dates

- Fresenius Kabi has cefotetan 10 gram vials on back order and the company estimates a release date of late-February to early-March 2017.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1097>

Ampicillin Sulbactam

January 31, 2017

Reason for the Shortage

- Mylan Institutional discontinued ampicillin sulbactam 1.5 gram and 3 gram vials.
- Pfizer has discontinued generic ampicillin sulbactam.
- Sandoz cannot provide a reason for the shortage.
- Sagent has ampicillin sulbactam vials on allocation due to increased demand for the product.
- WG Critical Care states the shortage was due to increased demand.

Estimated Resupply Dates

- AuroMedics has ampicillin sulbactam 1.5 gram, 3 gram, and 15 gram vials on intermittent back order and the company is releasing product as it becomes available.
- Fresenius Kabi has ampicillin sulbactam 1.5 gram, 3 gram, and 15 gram vials on back order and the company cannot estimate a release date.
- Mylan Institutional has ampicillin sulbactam 15 gram bulk vials on back order and the company estimates a release date of late-March 2017.
- Sagent has ampicillin sulbactam 3 gram and 15 gram vials on back order and the company estimates a release date of February 2017.
- Sandoz has ampicillin sulbactam 1.5 gram, 3 gram, and 15 gram vials temporarily unavailable and the company cannot estimate a release date.
- West-Ward has ampicillin sulbactam 1.5 gram and 3 gram vials on a weekly allocation. The 15 gram vials are on back order and the company cannot estimate a release date.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=805>

Ammonium Chloride Injection

January 31, 2017

Reason for the Shortage

- Pfizer discontinued ammonium chloride in late-October 2016.
- Pfizer was the sole manufacturer of ammonium chloride injection.

Estimated Resupply Dates

- Pfizer discontinued ammonium chloride 5 mEq/mL 20 mL vials.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=933>

Scopolamine Transdermal Patch

February 06, 2017

Reason for the Shortage

- Baxter had Transderm Scop on shortage due to a manufacturing hold.
- Baxter changed their NDC numbers in late 2016.

- Sandoz had Transderm Scop on shortage due to increased demand.
- Sandoz changed their NDC number in late 2016.

Estimated Resupply Dates

- Baxter has Transderm Scop in 10 count and 24 count available.
- Sandoz has Transderm Scop in 4 count on back order and the company estimates a release date of late-February 2017.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=837>

Penicillin G Benzathine/Penicillin G Procaine

February 06, 2017

Reason for the Shortage

- Pfizer has Bicillin C-R and Bicillin C-R 900/300 on shortage due to manufacturing delays.

Estimated Resupply Dates

- Pfizer has Bicillin C-R 1,200,000 units/2 mL prefilled syringes and 1,200,000 units/2 mL pediatric prefilled syringes on allocation.
- Pfizer has Bicillin C-R 900/300 2 mL pediatric prefilled syringes on allocation.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1249>

Cefepime Injection

February 06, 2017

Reason for the Shortage

- Apotex could not provide a reason for the shortage.
- BBraun has cefepime on allocation due to increased demand.
- Baxter has cefepime on shortage due to increased demand.
- Fresenius Kabi had cefepime injection on shortage due to manufacturing delays.
- Sagent has cefepime injection on shortage due to manufacturing delays.
- WG Critical Care has cefepime injection on shortage due to increased demand.
- Pfizer has Maxipime on shortage due to manufacturing delays.
- Sandoz discontinued cefepime injection in early 2016.

Estimated Resupply Dates

- Apotex has cefepime 1 gram vials in 1 count on back order and the company estimates a release date of mid-February 2017. The 1 gram vials in 10 count and 2 gram vials in 1 count are on back order and the company estimates a release date of late-February 2017.
- Braun has cefepime 1 and 2 gram premixed bags on allocation to contracted customers.
- Baxter has cefepime 1 gram/50 mL and 2 gram/100 mL premixed bags on allocation.
- Pfizer has Maxipime 1 gram ADD-Vantage vials, 2 gram ADD-Vantage vials, and 2 gram vials on allocation. The 1 gram vials are on back order and the company estimates a release date of March 2017.
- Sagent has cefepime 1 gram and 2 gram vials on back order and the company estimates a release date of February 2017.
- WG Critical Care has cefepime 1 gram and 2 gram vials on intermittent back order and is releasing product as it becomes available to contracted customers.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1176>

Amoxicillin and Clavulanate 1000 mg/62.5 mg Extended-Release Tablets

February 06, 2017

Reason for the Shortage

- Dr. Reddy's states they are having raw ingredient issues.
- Sandoz did not provide a reason for the shortage.

Estimated Resupply Dates

- Dr. Reddy's has Augmentin XR and generic amoxicillin/clavulanate 1000 mg / 62.5 mg tablets on back order and the company cannot estimate a release date.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1259>

Tetracaine Hydrochloride Ophthalmic Drops

February 07, 2017

Reason for the Shortage

- Valeant and OCuSOFT did not provide a reason for the shortage.

Estimated Resupply Dates

- OCuSOFT has Tetravisc 0.5% 5 mL bottles and 0.6 mL unit-dose containers in 12 count on back order and the company cannot estimate a release date.
- OCuSOFT has Tetravisc Forte 0.5% 5 mL bottles and 0.6 mL unit-dose containers in 12 count on back order and the company cannot estimate a release date.
- Valeant has tetracaine 0.5% 15 mL bottles on back order and the company estimates a release date in mid-February 2017.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1242>

Sodium Chloride 0.9% Injection Bags

February 07, 2017

Reason for the Shortage

- Baxter discontinued 0.9% sodium chloride 250 mL and 500 mL AVIVA bags. The other presentations are available or on allocation.
- BBraun has 0.9% sodium chloride available for current customers.
- Hospira cites increased demand as the reason for the shortage.
- Fresenius Kabi is no longer importing product.
- Baxter has received FDA approval for 0.9% sodium chloride in Viaflo containers manufactured in an FDA-approved facility in Spain.

Estimated Resupply Dates

- Baxter has 0.9% sodium chloride in 250 mL Viaflex bags on allocation. The 1000 mL Viaflex bags are on back order and the company estimates a release date in early-February 2017.
- BBraun has 0.9% sodium chloride in 250 mL, 500 mL, and 1000 mL PVC/DEHP-free bags on allocation.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=993>

Reteplase Injection

February 07, 2017

Reason for the Shortage

- Chiesi USA acquired Cornerstone Therapeutics in March 2014. Cornerstone Therapeutics acquired EKR Therapeutics in June 2012.
- EKR Therapeutics had previously purchased Retavase from PDL BioPharma.
- Cornerstone Therapeutics was seeking FDA approval of a new supplier of the active pharmaceutical ingredient for Reteplase.

Estimated Resupply Dates

- Chiesi USA has Retavase on long-term back order and the company cannot estimate a release date.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=569>

Potassium Chloride Injection

February 07, 2017

Reason for the Shortage

- Baxter has a consistent supply of potassium chloride injection.
- Fresenius Kabi has some potassium chloride injection available.
- Hospira has potassium chloride injection on shortage due to increase demand and manufacturing delays.

Estimated Resupply Dates

- Fresenius Kabi has potassium chloride 20 mEq/10 mL on back order and the company estimates a release date in early to mid-March 2017.
- Hospira has potassium chloride 2 mEq/mL 250 mL vials and 10 mEq/500 mL in 5% dextrose and 0.225% sodium chloride on back order and the company cannot estimate a release date.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=696>

Oxytocin Injection

February 07, 2017

Reason for the Shortage

- Fresenius Kabi states the shortage was due to increased demand.
- Par Sterile Products (formerly JHP) discontinued generic oxytocin injection in July 2014. Par Sterile Products discontinued Pitocin 10 unit/mL 50 mL vials in September 2015.
- West-Ward is not actively marketing oxytocin.

Estimated Resupply Dates

- Fresenius Kabi has oxytocin 10 units/mL 1 mL vials on intermittent back order and the company is releasing product as it is available.
- The 10 mL vials are available with an expiration date of <8 months.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=876>

Ondansetron Injection

February 07, 2017

Reason for the Shortage

- AuroMedics did not provide a reason for the shortage.
- Fresenius Kabi has ondansetron injection available.
- Heritage has ondansetron injection available.
- Mylan Institutional has ondansetron injection available.
- Novartis has Zofran injection available.
- Pfizer has ondansetron injection available.
- Sagent has ondansetron injection available.
- West-Ward has ondansetron injection available.
- Wockhardt has ondansetron injection on an FDA import alert.

Estimated Resupply Dates

- AuroMedics has ondansetron 2 mg/mL 2 mL and 20 mL vials on intermittent back order and the company is releasing product as it becomes available.
- Teva has ondansetron 2 mg/mL 20 mL vials in 1 and 10 count on long-term back order and the company cannot estimate a return date.
-

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1040>

Liotrix Tablets

February 07, 2017

Reason for the Shortage

- Thyrolar tablets from Actavis (formerly Forest) are on shortage due to manufacturing changes

Estimated Resupply Dates

- Actavis (formerly Forest) has all Thyrolar presentations on long-term back order and the company cannot estimate a release date.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=24>

Lidocaine Topical 4% Solution

February 07, 2017

Reason for the Shortage

- Amphastar did not provide a reason for the shortage.
- Teligent did not provide a reason for the shortage.
- West-Ward did not provide a reason for the shortage.

Estimated Resupply Dates

- Amphastar has Laryng-O-Jet topical solution 4 mL syringes available in limited quantities and the company estimates they will have additional product in mid-February 2017.
- Teligent has lidocaine topical 4% solution in 50 mL bottles on allocation.
- West-Ward has lidocaine topical 4% solution in 50 mL bottles on back order and the company estimates a release date in late-March 2017

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1128>

Levocarnitine Oral Tablets and Solution

February 07, 2017

Reason for the Shortage

- Akorn has levocarnitine tablets available.
- Sigma-Tau has Carnitor presentations on shortage due to increased demand.

Estimated Resupply Dates

- Akorn has levocarnitine oral solution on allocation.
- Sigma-Tau has Carnitor tablets on allocation.
- Sigma-Tau has Carnitor 100 mg/mL oral solution and Carnitor SF 100 mg/mL Sugar-Free oral solution on allocation.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1254>

loversol Injection

February 07, 2017

Reason for the Shortage

- Guerbet could not provide a reason for the Optiray shortage.

Estimated Resupply Dates

- Guerbet has most Optiray products on allocation.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1253>

Hydroxyamphetamine Hydrobromide and Tropicamide Ophthalmic Solution

February 07, 2017

Reason for the Shortage

- Akorn has Paremyd on shortage due to manufacturing delays.
- No clinical trial data were found to support the use of Paremyd in the diagnosis of Horner Syndrome.

Estimated Resupply Dates

- Akorn has Paremyd ophthalmic solution on back order and the company estimates a release date of early-March 2017.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1193>

Hepatitis A Virus Vaccine Inactivated

February 07, 2017

Reason for the Shortage

- Merck did not provide a reason for the Vaqta shortage.
- GlaxoSmithKline did not provide a reason for the Havrix shortage.

Estimated Resupply Dates

- Merck has Vaqta pediatric/adolescent formulation 25U/0.5 mL prefilled syringes in 10 count on back order and the company estimates a release date in 2nd quarter 2017.

- Merck has Vaqta adult formulation 50U/1 mL vials in 1 count on back order and the company estimates a release date in 2nd quarter 2017. Merck has limited availability of short-dated Vaqta adult formulation 50U/1 mL vials in 10 count. Vaqta 50U/1 mL vials in 10 count with regular dating are on back order and the company estimates a release date in 2nd quarter 2017.
- GlaxoSmithKline Vaccines has Havrix adult syringes and Havrix adult single dose vials in 10 count on back order and the company estimates a release date in May 2017.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=180>

Haloperidol Lactate Injection

February 07, 2017

Reason for the Shortage

- Patriot Pharmaceuticals has haloperidol lactate available.
- Sagent has haloperidol lactate on shortage due to manufacturing delays.
- Teva has haloperidol lactate on shortage due to manufacturing delays.
- West-Ward Pharmaceuticals' parent company, Hikma Pharmaceuticals, acquired several products from Bedford Laboratories in July 2014 including haloperidol lactate injection. West-Ward is not actively marketing haloperidol lactate at this time.
- Janssen has Haldol injection available.

Estimated Resupply Dates

- Teva has haloperidol lactate 5 mg/mL 10 mL vials on back order and the company cannot estimate a release date.
- Sagent has haloperidol lactate 5 mg/mL 10 mL vials on back order and the company cannot estimate a release date. Haloperidol lactate 5 mg/mL 1 mL vials are on back order and the company estimates a release date in February 2017.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=527>

Clindamycin Injection

February 07, 2017

Reason for the Shortage

- Akorn cannot provide a reason for the shortage.
- Pfizer has Cleocin available.
- Alvogen has clindamycin injection available.
- Sandoz has clindamycin injection available.
- Sagent has clindamycin injection available.

Estimated Resupply Dates

- Akorn has clindamycin 900 mg/50 mL premixed bottles on back order and the company estimates a release date of mid-February 2017.
- Fresenius Kabi has clindamycin 150 mg/mL 2 mL and 4 mL vials available with short expiration dating of <5 months for the 2 mL vials and <7 months for the 4 mL vials.
- Sagent has clindamycin 150 mg/mL 60 mL bulk vials available with an expiration date of June 2017.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1029>

Cefoxitin Sodium Injection

February 07, 2017

Reason for the Shortage

- Fresenius Kabi and West-Ward did not provide a reason for the shortage.
- Sagent has cefoxitin on shortage due to manufacturing delays.
- BBraun has cefoxitin on allocation due to increased demand.

Estimated Resupply Dates

- Apotex has cefoxitin 10 gram vials available in limited quantities with an expiration date of October 2017. The 2 gram vials are on back order and the company cannot estimate a resupply date.
- BBraun has cefoxitin 2 gram premixes on back order and the company cannot estimate release date. Check wholesalers for inventory.
- Sagent has cefoxitin 2 gram and 10 gram vials on back order and the company estimates a release date of February 2017.
- West-Ward has cefoxitin 1 gram, 2 gram, and 10 gram vials on back order and the company estimates a release date of March or April 2017.
- WG Critical Care has cefoxitin 10 gram vials on back order and the company estimates a release date of early-March 2017.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1256>

Bupivacaine with epinephrine Injection

February 07, 2017

Reason for the Shortage

- Fresenius Kabi has bupivacaine and epinephrine on shortage due to increased demand and manufacturing delays.
- Pfizer has bupivacaine with epinephrine on shortage due to manufacturing delays.

Estimated Resupply Dates

- Fresenius Kabi has 0.25% Sensorcaine-MPF with epinephrine 10 mL vials and 0.5% Sensorcaine-MPF with epinephrine 10 mL vials on back order and the company estimates a release date of mid-April 2017. Fresenius Kabi has 0.25% Sensorcaine-MPF with epinephrine 30 mL vials on back order and the company estimates a release date of early-February 2017. The 0.25% Sensorcaine with epinephrine 50 mL vials are on back order and the company estimates a release date of early-February 2017. The 0.5% Sensorcaine-MPF with epinephrine 30 mL vials are on back order and the company estimates a release date of mid-February 2017. The 0.5% Sensorcaine-MPF with epinephrine 30 mL vials sterile packs are on back order and the company estimates a release date of late-February to early-March 2017. The 0.5% Sensorcaine with epinephrine 50 mL vials are on back order and the company estimates a release date of early-February 2017.
- Pfizer has 0.25% bupivacaine with epinephrine 10 mL and 30 mL preservative-free vials available in limited supply. The 0.25% bupivacaine with epinephrine 50 mL vials are on back order and the company estimates a release date of late-February 2017. The 0.5% bupivacaine with epinephrine 10 mL and 30 mL preservative-free vials are available in limited supply.
- Pfizer has 0.25% Marcaine with epinephrine 10 mL and 30 mL preservative-free vials available in limited supply. The 0.25% Marcaine 50 mL vials are on back order and the company estimates a release date of late-February 2017. The 0.5% Marcaine with epinephrine 10 mL preservative-free vials are on back order and the company estimates a release date of late-March 2017. The 0.5% Marcaine 50 mL vials are on back order and the company estimates a release date of late-February 2017.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=937>

Ampicillin Injection

February 07, 2017

Reason for the Shortage

- AuroMedics cannot provide a reason for the shortage.
- Fresenius Kabi has ampicillin injection available.
- Sagent states the reason for the shortage is manufacturing delay.
- Sandoz could not provide a reason for the shortage.
- WG Critical Care has ampicillin injection available.

Estimated Resupply Dates

- AuroMedics has ampicillin 250 mg, 500 mg, 1 gram, 2 gram, and 10 gram vials on intermittent back order and the company is releasing product as it becomes available.
- Sagent has ampicillin 250 mg vials on allocation.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1226>

Ofloxacin Ophthalmic Solution

February 09, 2017

Reason for the Shortage

- Allergan has Ocuflax ophthalmic solution available.
- Akorn did not provide a reason for the shortage.
- Rising has ofloxacin ophthalmic solution available.
- Valeant did not provide a reason for the shortage.

Estimated Resupply Dates

- Akorn has ofloxacin ophthalmic solution in 5 mL bottles on back order and the company estimates a release date of mid-March 2017.
- Valeant has temporarily discontinued ofloxacin ophthalmic solution in 5 mL and 10 mL bottles and the company cannot estimate a release date.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1235>

Nitroglycerin Injection

February 09, 2017

Reason for the Shortage

- American Regent did not provide a reason for the shortage.
- The premixed bags are not affected by this shortage.

Estimated Resupply Dates

- American Regent has nitroglycerin 50 mg/mL 10 mL vials on short-term back order and the company cannot estimate a release date.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=786>

Lorazepam injectable presentations

February 09, 2017

Reason for the Shortage

- Bedford discontinued lorazepam injection in May, 2011.
- West-Ward had product on shortage due to manufacturing delays.
- Pfizer had product on shortage due to increased demand.
- Akorn has not provided a reason for the shortage.
- Amphastar has product available.

Estimated Resupply Dates

- Akorn has lorazepam 2 mg/mL 2 mL vials available in limited supply.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=747>

Disopyramide Phosphate Controlled-release Capsules

February 09, 2017

Reason for the Shortage

- Pfizer has disopyramide controlled-release capsules on shortage due to manufacturing delays.

Estimated Resupply Dates

- Pfizer has Norpace CR available but with short-expiration dating.
- The 100 mg capsules in 100 count and 500 count and 150 mg capsules in 500 count have an expiration date of May 2017.
- The 150 mg capsules in 100 count have an expiration date of June 2017.
- Once this supply is depleted the estimated release date for all presentations is late-1st quarter 2018.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1139>

Atropine Sulfate Ophthalmic Solution

February 09, 2017

Reason for the Shortage

- Alcon has discontinued Isopto Atropine.
- Akorn received FDA approval for atropine sulfate 1% ophthalmic solution in July 2014; this new product launched in January 2015.
- Sandoz has discontinued atropine sulfate ophthalmic solution.
- Valeant discontinued their atropine sulfate 1% ophthalmic solution products in 2015.

Estimated Resupply Dates

- Akorn has atropine sulfate ophthalmic solution in 2 mL bottles on allocation.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1146>

Tobramycin Injection

February 10, 2017

Reason for the Shortage

- Akorn has tobramycin injection on shortage due to manufacturing delays.

- Mylan Institutional could not provide a reason for the shortage.

Estimated Resupply Dates

- Akorn has tobramycin 40 mg/mL 2 mL and 30 mL vials on back order and the company cannot estimate a release date.
- Mylan Institutional has tobramycin 40 mg/mL 2 mL vials on back order and the company estimates a release date of mid-February 2017.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=701>

Talc, Sterile

February 10, 2017

Reason for the Shortage

- Lymol has Sclerosol and talc powder on shortage due to manufacturing delays.
- There are no other commercially available suppliers of sterile talc.

Estimated Resupply Dates

- Lymol has Sclerosol and talc powder on long-term back order and the company cannot estimate a release date.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1248>

Carboplatin Solution for Injection

February 10, 2017

Reason for the Shortage

- Bedford discontinued carboplatin in May, 2011 to concentrate on the manufacturing of other products.
- Fresenius Kabi has carboplatin on shortage due to increased demand for the product.
- Mylan Institutional cannot provide a reason for the shortage.
- Pfizer has carboplatin injection available.
- Sagent states the reason for the shortage is increased demand for the product.
- Sandoz has discontinued carboplatin injection.
- Teva states the reason for the shortage is increased demand for the product.

Estimated Resupply Dates

- Fresenius Kabi has carboplatin 45 mL vials available with an expiration date of <7 months.
- Mylan Institutional has all carboplatin injection on back order and the company cannot estimate a release date.
- Sagent has carboplatin 5 mL, 15 mL, 45 mL, and 60 mL vials on back order and the company cannot estimate a release date.
- Teva has carboplatin 60 mL vials on allocation.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1005>

Sodium Nitroprusside Injection

February 13, 2017

Reason for the Shortage

- Valeant has Nitropress available.

- Sagent launched sodium nitroprusside in late 2016. They have product available.

Estimated Resupply Dates

- Valeant has Nitropress 25 mg/mL 2 mL vials available with an expiration date of February 2018.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1223>

Ranitidine Injection

February 13, 2017

Reason for the Shortage

- West-Ward discontinued ranitidine injection in September 2014.
- Covis had Zantac on shortage due to capacity issues at the manufacturer.
- IGI laboratories acquired Zantac injection from Covis in October 2015.
- Zydus had temporarily discontinued ranitidine injection due to stability issues.
- Oral ranitidine products are not affected by this shortage.

Estimated Resupply Dates

- Teligent has Zantac 25 mg/mL 6 mL vials on back order and the company estimates a release date of mid-February 2017.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=820>

Lidocaine Hydrochloride Oral Topical Solution (Viscous) 2%

February 13, 2017

Reason for the Shortage

- West-Ward did not provide a reason for the viscous lidocaine shortage.
- Akorn has viscous lidocaine available.

Estimated Resupply Dates

- West-Ward has viscous lidocaine 100 mL bottles on back order and the company estimates a release date in late-March 2017.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1171>

Levetiracetam Injection

February 13, 2017

Reason for the Shortage

- American Regent has product available.
- AuroMedics has product available.
- Caraco will not provide availability information on levetiracetam.
- Fresenius Kabi has levetiracetam injection on shortage due to manufacturing delays.
- Mylan has product available.
- Pfizer has product available.
- Sagent has product available.
- UCB has product available.
- West-Ward has product available.
- X-Gen has product available.

Estimated Resupply Dates

- Fresenius Kabi has levetiracetam 100 mg/mL 5 mL vials on back order and the company estimates a release date of early-March 2017.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1183>

Dexamethasone Sodium Phosphate

February 13, 2017

Reason for the Shortage

- American Regent has dexamethasone sodium phosphate on shortage due to manufacturing delays.
- AuroMedics had dexamethasone sodium phosphate on intermittent back order.
- Fresenius Kabi has dexamethasone sodium phosphate presentations available.
- West-Ward did not provide a reason for the shortage.
- Mylan Institutional has dexamethasone sodium phosphate available.

Estimated Resupply Dates

- American Regent has dexamethasone sodium phosphate 4 mg/mL products on back order and the company cannot estimate a release date.
- AuroMedics has dexamethasone sodium phosphate 4 mg/mL 1 mL vials on intermittent back order and the company is releasing product as it becomes available.
- West-Ward has dexamethasone sodium phosphate 10 mg/mL 1 mL vials on allocation.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=751>

Acetylcysteine Oral and Inhalation Solution

February 13, 2017

Reason for the Shortage

- American Regent has acetylcysteine oral and inhalation solution on shortage due to manufacturing delays.
- Fresenius Kabi states the reason for the shortage is shipping delays.
- Pfizer has acetylcysteine oral and inhalation solution available.
- Roxane Labs discontinued acetylcysteine oral and inhalation solution in April 2014.

Estimated Resupply Dates

- American Regent has acetylcysteine solution 100 mg/mL 10 mL vials, and 200 mg/mL 10 mL and 30 mL vials on back order and the company cannot estimate a release date.
- Fresenius Kabi has acetylcysteine solution 200 mg/mL 10 mL vials and 100 mg/mL 30 mL vials on back order and the company estimates a release date of late-February 2017. Acetylcysteine solution 100 mg/mL 4 mL vials are available with a short expiration date (<5 months).

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=932>

Acetazolamide Injection

February 13, 2017

Reason for the Shortage

- West-Ward is not actively marketing acetazolamide injection at this time.
- Sagent has acetazolamide injection on shortage due to manufacturing delays.
- X-Gen has acetazolamide injection on shortage due to manufacturing delays.

Estimated Resupply Dates

- Sagent has acetazolamide 500 mg vials on back order and the company estimates a release date of March 2017.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=463>

Rocuronium Injection

February 14, 2017

Reason for the Shortage

- Fresenius Kabi has rocuronium on shortage due to delay of raw materials.
- Pfizer has rocuronium on shortage due to manufacturing delays.
- Sagent has rocuronium on shortage due to increased demand.

Estimated Resupply Dates

- Fresenius Kabi has rocuronium 10 mg/mL 5 mL and 10 mL vials on back order and the company estimates a release date of mid-February 2017.
- Pfizer has rocuronium 10 mg/mL 5 mL and 10 mL vials available in limited supply.
- Sagent has rocuronium 10 mg/mL 5 mL and 10 mL vials on back order and the company estimates a release date of March 2017 for the 5 mL vials and February 2017 for the 10 mL vials.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=434>

Mitoxantrone Hydrochloride Injection

February 14, 2017

Reason for the Shortage

- Fresenius Kabi has mitoxantrone on shortage due to increased demand.
- Hospira has mitoxantrone injection on shortage due to manufacturing delay.
- Teva has mitoxantrone injection on allocation due to current market conditions.

Estimated Resupply Dates

- Fresenius Kabi has mitoxantrone 10 mL vials on back order and the company estimates a release date of late-February to early-March 2017.
- Hospira has all mitoxantrone injection on long-term back order and the company estimates a release date of early-4th quarter 2017.
- Teva has mitoxantrone 10 mL vials temporarily unavailable and the company cannot estimate a release date.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1212>

Lidocaine with Epinephrine Injection

February 14, 2017

Reason for the Shortage

- Fresenius Kabi has Xylocaine with epinephrine presentations on shortage due to increased demand for the product and manufacturing delays.
- Pfizer has lidocaine with epinephrine presentations on shortage due to manufacturing delays.

Estimated Resupply Dates

- Pfizer has 1% lidocaine with epinephrine (1:100,000) 30 mL and 50 mL vials available in limited supply. The 0.5% lidocaine with epinephrine (1:200,000) 50 mL vials and 2% lidocaine with epinephrine (1:200,000) 20 mL vials are available in limited supply. The 2% lidocaine with epinephrine (1:100,000) 20 mL and 30 mL vials are available in limited supply.
- Fresenius Kabi has 0.5% Xylocaine with epinephrine (1:200,000) 50 mL vials on back order and the company estimates a release date of mid-February 2017. The 1% Xylocaine with epinephrine (1:200,000) 10 mL, 20 mL, and 50 mL vials are on back order and the company estimates a release date of mid-April 2017 for the 10 mL vials, mid-February 2017 for the 20 mL vials, and late-February 2017 for the 50 mL vials. The 1% Xylocaine-MPF with epinephrine (1:200,000) 10 mL vials are on back order and the company estimates a release date of mid-April 2017. The 1.5% Xylocaine-MPF with epinephrine (1:200,000) 10 mL vials are on back order and the company estimates a release date of mid-April 2017. The 2% Xylocaine-MPF with epinephrine (1:200,000) 10 mL vials are on back order and the company estimates a release date of mid-April 2017. The 2% Xylocaine-MPF with epinephrine (1:200,000) 20 mL vials in sterile packs are on back order and the company cannot estimate a release date.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=860>

Leucovorin Calcium Injection

February 14, 2017

Reason for the Shortage

- Fresenius Kabi has leucovorin on shortage due to increase demand.
- Teva has leucovorin on allocation due to increased demand.
- West-Ward has leucovorin available.
- Sagent has leucovorin on shortage due to manufacturing delay.

Estimated Resupply Dates

- Fresenius Kabi has leucovorin 200 mg and 500 mg vials on back order and the company estimates a release date of late-February to early-March 2017 for the 200 mg vials and late-March 2017 for the 500 mg vials.
- Sagent has leucovorin 50 mg and 200 mg vials on back order and the company estimates a release date of February 2017. The 100 mg and 350 mg vials are on allocation.
- Teva has leucovorin 100 mg and 350 mg vials on allocation.
- West-Ward has leucovorin 350 mg vials on a weekly allocation.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=488>

Indigo Carmine Injection

February 14, 2017

Reason for the Shortage

- Akorn did not provide a reason for the hydralazine injection on shortage.
- American Regent has hydralazine injection on shortage due to manufacturing delays.
- Fresenius Kabi has hydralazine injection available.
- X-Gen launched hydralazine injection in September 2015.

Estimated Resupply Dates

- American Regent has hydralazine 20 mg/mL 1 mL vials on back order and the company cannot estimate a release date.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1129>

Fludarabine Injection

February 14, 2017

Reason for the Shortage

- Actavis has fludarabine available.
- Fresenius Kabi has fludarabine on shortage due to increased demand.
- Pfizer has fludarabine on shortage due to increased demand.
- Sagent had fludarabine lyophilized powder on shortage due to manufacturing delays. They are no longer marketing fludarabine 25 mg/mL 2 mL vials.

Estimated Resupply Dates

- Fresenius Kabi has fludarabine 25 mg/mL 2 mL vials on back order and the company estimates a release date of early-April 2017.
- Pfizer has fludarabine lyophilized powder 50 mg vials on back order and the company estimates a release date of late-1st quarter 2017.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=648>

Promethazine Injection

February 15, 2017

Reason for the Shortage

- Teva is not marketing promethazine injection at this time.
- West-Ward states the shortage was due to manufacturing delays.
- Hospira discontinued promethazine in 2016.
- X-Gen has promethazine available.

Estimated Resupply Dates

- West-Ward has promethazine 25 mg/mL 1 mL vials and ampules and 50 mg/mL 1 mL vials on back order and the company cannot estimate a release date. Phenergan 25 mg/mL 1 mL vials are on back order and the company cannot estimate a release date. Phenergan 25 mg/mL 1 mL ampules are on a weekly allocation.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=654>

Labetalol Injection

February 15, 2017

Reason for the Shortage

- Akorn has labetalol injection on shortage due to increased demand.
- Pfizer has labetalol injection on shortage due to manufacturing delays.

Estimated Resupply Dates

- Akorn has labetalol 5 mg/mL 40 mL vials on back order and the company estimates a release date of late-February 2017.
- Pfizer has labetalol 5 mg/mL 4 mL Carpuject syringes on back order and the company estimates a release date of late-February 2017.
- The 20 mL and 40 mL vials are on back order and the company estimates a release date of late-February 2017 for the 20 mL vials and early-April 2017 for the 40 mL vials.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=397>

Intranasal Mucosal Atomization Device

February 15, 2017

Reason for the Shortage

- Teleflex Medical has recalled multiple lots of MAD nasal devices due to potential for inaccurate delivery of atomized medications.
 - There have been several reports of the lots producing streams of medication instead of atomized sprays.
- Available Products There is insufficient supply for usual ordering.

Estimated Resupply Dates

- Teleflex Medical has LMA MAD Nasal Intranasal Mucosal Atomization Devices on allocation.

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1255>

Sodium Bicarbonate Injection

February 15, 2017

Reason for the Shortage

- Amphastar has sodium bicarbonate injection on shortage due to manufacturing delays.
- Pfizer has sodium bicarbonate injection on shortage due to manufacturing delays.

Estimated Resupply Dates

- Amphastar has 8.4 % sodium bicarbonate 50 mL syringes available in limited supply.
- Pfizer has 8.4 % sodium bicarbonate 50 mL syringes and 50 mL vials available in limited supply.
- The 8.4% 10 mL syringes are on back order and the company estimates a release date of mid-March 2017.

<http://ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=788>